The protection against the cerebral and pulmonary effects of hyperbaric oxygen by pharmacological agents and lithium salts in mice.
D000085:Acetates / Q000627:therapeutic use; D000613:Aminobutyrates / Q000627:therapeutic use; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001921:Brain / Q000378:metabolism; D002746:Chlorpromazine / Q000627:therapeutic use; D005260:Female; D006885:Hydroxybutyrates / Q000627:therapeutic use; D006931:Hyperbaric Oxygenation / Q000009:adverse effects*; D008094:Lithium / Q000627:therapeutic use*; D008168:Lung / Q000032:analysis; D051379:Mice; D010080:Oxazoles / Q000627:therapeutic use; D010634:Phenobarbital / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D011346:Prochlorperazine / Q000627:therapeutic use; D011395:Promazine / Q000627:therapeutic use; D011654:Pulmonary Edema / Q000517:prevention & control*; D012640:Seizures / Q000150:complications / Q000517:prevention & control*; D014867:Water / Q000032:analysis
D000085:Acetates; D000613:Aminobutyrates; D000927:Anticonvulsants; D014150:Antipsychotic Agents; D006885:Hydroxybutyrates; D010080:Oxazoles; D014867:Water; D010672:Phenytoin; D008094:Lithium; D011395:Promazine; D002746:Chlorpromazine; D011346:Prochlorperazine; D010634:Phenobarbital